These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19859999)

  • 1. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
    Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
    World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
    BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
    Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
    Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
    Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
    Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
    Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY
    Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
    Trials; 2016 Jan; 17():46. PubMed ID: 26811156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
    Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
    World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
    Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
    Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
    Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
    Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
    Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.